A study in England found that vaccinating pregnant women against RSV cut infant hospital admissions by roughly 80%[1].

Reducing severe RSV cases matters because the virus is the leading cause of lower‑respiratory‑tract infection in babies, often requiring costly hospital care and posing a risk of lasting lung damage.

The research, published in December 2023, analysed nearly 300,000 babies born during the 2022‑2023 RSV season[2]. It compared hospital records of infants whose mothers received the vaccine with those whose mothers did not.

Around 64% of pregnant women in England received the RSV vaccine[1], though uptake fell to 53% in London[1]. These figures show a strong national rollout but also highlight regional gaps.

The vaccine prompts mothers to produce antibodies—protective proteins that cross the placenta—to shield newborns from severe RSV infection.

Prof. Peter Openshaw said, "The vaccine offers excellent protection for babies against life‑threatening chest infections."[1]

Dr. Andrew J. Pollard said, "Vaccinating expectant mothers reduces hospital admissions in young infants by at least 80 per cent."[2]

Dr. Emma L. Jones said, "Our findings show a dramatic fall in RSV‑related admissions among infants whose mothers were vaccinated during pregnancy."[3]

Health officials see the results as a catalyst for expanding maternal immunization programs, potentially adding RSV protection to the existing suite of vaccines given during pregnancy.

**What this means** The data suggest that widespread maternal RSV vaccination could dramatically lower infant hospital burdens and mortality, prompting the UK and other countries to consider national roll‑outs as a cost‑effective public‑health strategy.

“"The vaccine offers excellent protection for babies against life‑threatening chest infections." – Prof. Peter Openshaw”

If the high vaccine uptake seen nationally can be matched in lower‑coverage areas, the United Kingdom could see a sustained drop in RSV‑related infant hospitalisations, easing pressure on paediatric services and setting a benchmark for other nations considering maternal RSV immunisation.